Press Releases
AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Pompe Disease
Pre-Clinical Program Becomes Company’s Third GeneTherapy for Lysosomal Storage Disorders Pre-Clinical Proof-of-Concept Demonstrated Cambridge, MA, September 20, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing
AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Gaucher Disease
Preclinical Proof-of-Concept Achieved, IND-Enabling Activities Underway Cambridge, MA, March 22, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the
AVROBIO, Inc. Expands Senior Management Team with Three Key Hires
Industry Veterans Bring Deep Industry Experience to Support Future Growth Cambridge, MA, November 9, 2016 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for
AVROBIO, Inc. Announces $25 Million Series A Financing to Advance Novel, Clinical-Stage Gene Therapies for Rare Diseases & Cancer
Company Leverages Disruptive Therapies to Create New Paradigms in the Treatment of Fabry Disease and Acute Myeloid Leukemia Cambridge, MA, August 2, 2016 – AVROBIO, Inc, a clinical-stage
AVROBIO Awarded Johnson & Johnson Coveted J-Labs Incubator Space
Cambridge, MA May 13, 2016 – AVROBIO, a clinical-stage biotechnology company developing transformative, life-changing gene therapies targeting rare diseases and cancer, today announced it has been awarded
AVROBIO Inc. Launches to Develop Novel, Clinical-Stage Cell and Gene Therapies Targeting Immuno-Oncology and Rare Diseases
Disruptive Therapies with Potential to Displace Standard of Care Treatments for Acute Myeloid Leukemia (AML) and Fabry Disease Announces Management Team of Industry Leaders with Unmatched Scientific,